Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma

BMC Ophthalmology

Table 1 Characteristics of patients with lacrimal gland adenoid cystic carcinoma

Case No.	Age (years)/Gender/Affected side	Duration of symptom (months)	Greatest dimension (mm)	PNI	8th AJCC stage	Treatment	LR/Met	Outcome
1	58/F/L	6	19	+	T1bN0M0	E + RT	no	NED
2	34/M/R	2	45	+	T3bN0M0	E + RT	LR/brain	DOD
3	56/M/L	6	20	–	T1aN0M0	E + RT + CT	no	NED
4	58/M/R	1	38	–	T2aN0M0	E + RT	no	NED
5	58/M/L	6	30	+	T2bN0M0	E + RT + CT	LR	NED
6	45/F/R	2	30	+	T2bN0M0	E + RT + CT	LR	NED
7	83/M/L	96	35	–	T2aN0M0	E + RT	LR/lung	DOD
8	59/F/L	8	26	+	T2bN0M0	E + RT	no	NED
9	38/M/L	6	38	+	T2bN0M0	E	LR	NED
10	54/F/L	12	55	+	T4cN0M1	E	LR/brain	DOD
11	51/F/L	12	24	+	T2bN0M0	E + RT + CT	LR/lung, brain	AWD
12	45/M/R	24	27	–	T2aN0M0	E	LR	NED
13	66/F/L	120	23	–	T2aN0M0	E + RT	no	NED
14	38/F/R	3	12	–	T1aN0M0	E + RT	LR	NED
15	44/F/R	24	20	–	T1aN0M0	E + RT + CT	lung	DOD
16	71/M/L	6	13	–	T1aN0M0	E + RT + CT	LR/liver	AWD
17	32/M/R	2	26	–	T2aN0M0	E + RT + CT	LR/lung, brain	DOD
18	52/M/R	2	45	+	T3bN0M0	E + RT + CT	LR/LN, brain	DOD
19	72/F/L	72	20	–	T1aN0M0	E + RT	LR/nose	AWD
20	36/F/L	2	22	+	T2bN0M0	E + RT + CT	no	NED
21	61/F/R	24	45	+	T3bN0M0	E + RT + CT	LR/brain	DOD
22	54/M/L	6	31	+	T2bN0M0	E + RT	no	NED
23	49/M/L	6	35	+	T2bN0M0	E + RT	LR/brain	DOD
24	63/M/L	24	20	–	T1aN0M0	E	no	NED

F female, M male, PNI perineural invasion E excision, RT postoperative radiation therapy, CT Chemotherapy, LR local recurrence, Met distant metastases, LN lymph node, DOD died of disease, NED no evidence of disease, AWD alive with metastatic disease

ISSN: 1471-2415